Showing 7691-7700 of 18164 results for "".
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
https://reachmd.com/programs/project-oncology/challenging-the-standard-of-care-in-nsclc-findings-from-the-tropion-lung01-study/16360/What role might datopotamab deruxtecan play in treating patients with non-small cell lung cancer? Find out with this recap of a recent study.How to Achieve Patient Satisfaction Through Culturally Aware Communication
https://reachmd.com/programs/lifelong-learning/how-to-achieve-patient-satisfaction-through-culturally-aware-communication/10019/Drs. Aboulsoud & Uhlmann enlighten healthcare teams on how to achieve patient satisfaction through cultural competence and cultural awareness.The Lancet: Postural Modification to the Standard Valsalva Maneuver for Emergency Treatment of Supraventricular Tachycardias (REVERT)
https://reachmd.com/programs/Audioabstracts/lancet-postural-modification-standard-valsalva-maneuver-emergency-treatment-svt-revert/7633/Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial Andrew Appelboam, FRCEM, Adam Reuben, FRCEM, Clifford Mann, FRCEM, James Gagg, FRCEM, Prof Paul Ewings, PhD, Andrew Barton, MSc, Trudie Lobban, MRAdvancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
https://reachmd.com/programs/neurofrontiers/advancing-schizophrenia-care-when-and-how-to-use-novel-therapies-in-complex-patients/36642/Treating schizophrenia is rarely a one-size-fits-all approach, especially for patients who’ve cycled through multiple antipsychotics with limited success. In these complex cases, knowing when and how to consider novel mechanisms of action beyond traditional D2-blocking agents is essential. Joining DClinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
https://reachmd.com/programs/project-oncology/tovorafenib-clinical-stability-pediatric-low-grade-glioma/37195/What if clinical stability in pediatric low-grade glioma could be maintained after treatment ends? Emerging data from the phase 2 FIREFLY-1 trial suggest that tovorafenib may offer durable off-therapy disease control, even in the presence of radiographic changes. With a 53% objective response rate,Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
https://reachmd.com/programs/cme/maximizing-outcomes-strategic-approaches-in-metastatic-crc-treatment/36513/Explore expert recommendations for optimizing clinical outcomes with targeted treatment combinations in BRAF-mutant mCRC.Personalizing Psoriasis Treatment: Key Considerations for Optimal Outcomes
https://reachmd.com/programs/clinicians-roundtable/personalizing-psoriasis-treatment-key-considerations-for-optimal-outcomes/32448/Here’s how we can address challenges in psoriasis treatment through tailored care.GA Cases in the Primary Eye Care Clinic: Vision Loss Protection
https://evolvemeded.com/series/2419-ga/ga-cases-primary-eye-care-clinic-vision-loss-protection/30025/Yasha S. Modi, MD, MHS, and Paula Pecen, MD, explain the potential functional benefits of GA treatment and present two cases.Treatment Selection Strategies for Metastatic Breast Cancer Patients
https://reachmd.com/programs/project-oncology/treatment-selection-strategies-for-metastatic-breast-cancer-patients/26819/Explore essential strategies for selecting a treatment option for patients with metastatic breast cancer.Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
https://reachmd.com/programs/project-oncology/early-adulthood-weight-breast-tissue-complexity/48767/